Dr. Gillis' Wellness Center review

Dr. Gillis’ Wellness Center publishes a named peptide menu, but its price lists disagree. NAD⁺ is $60 in the official image and both linked PDFs, without a billing period or supply. GHK-Cu is $185 in the image and $100 in both PDFs; Wolverine is $60 in the image and $100 or $80 in the PDFs. CJC-1295/ipamorelin is advertised at $185 monthly on the medication page. These are advertised amounts, not verified treatment quotes. Confirm the selected price, contents, supply and state eligibility before paying.

Dr. Gillis' Wellness Center is a clinic at 8 Water Street in Oakland, Maine, founded in 2023 and led by Dr. Gillis, a board-certified physician and surgeon with more than 25 years in gut health and gastrointestinal surgery. He sits on the State Medical Board in Augusta and holds hospital privileges at MaineGeneral and St. Mary's. The peptide menu names sermorelin, CJC-1295/ipamorelin, tesamorelin, GHK-Cu, glutathione, NAD⁺ and a "Wolverine" blend of BPC-157 and TB-500. Alongside it are compounded semaglutide, tirzepatide and retatrutide, oral GLP-1 options, testosterone therapy for men, and in-clinic body-contouring treatments.

A small clinic with a real physician's name on it. Consultations are free every Wednesday afternoon, follow-up appointments are free, and there are no contracts: you choose a weekly, every-two-weeks or monthly injection schedule. The exact first debit, renewal schedule and cancellation or refund terms are unconfirmed; no contracts does not promise an order refund. Telehealth appointments are offered, but the reach is unclear: the homepage describes telehealth throughout Central Maine, while the FAQ says telehealth is available nationwide. So confirm eligibility for your state before going further. The clinic does not name its compounding pharmacy, and no baseline lab step is described for the growth-hormone-axis peptides, where an IGF-1 baseline is the obvious thing to want. HSA and FSA cards are accepted; insurance is not.

The medication page advertises CJC-1295/ipamorelin at $185 a month and the glutathione Meno Shot from $40 a month. Sermorelin is listed as "$165/.2mL | $200/.3mL", without an established monthly supply or concentration.

The official price-list image and both linked PDFs list NAD⁺ at $60. Those entries give no billing period, quantity or supply duration, so $60 is not an established monthly cost. GHK-Cu is $185 in the image and $100 in both PDFs. Wolverine is $60 in the image, $100 in the first PDF and $80 in the second. Both PDFs list CJC-1295/ipamorelin at $185 without a period; the separate medication page supplies its monthly claim. Tesamorelin has no established price. Obtain a written selected-product quote rather than choosing whichever price is lowest.

Weight-loss advertising also differs: a $150 semaglutide starting-dose promotion appears alongside $200 monthly semaglutide and $300 monthly tirzepatide claims. Charts list semaglutide at $225–$475 and tirzepatide at $325–$525 for listed amounts, without a billing period. The $25 cash discount is specific to semaglutide and tirzepatide. TRT’s medication page has an $85 monthly heading and an $80 monthly body price; charts show $85 and a higher-dose $100 without a period. None establishes a selected treatment total.

Free Wednesday consultations and follow-ups are advertised; public pages give differing afternoon consultation hours. Confirm availability, required labs, shipping, the initial charge, later charges and refund terms. The chosen injection schedule does not itself establish how much medication an order supplies or when it is billed.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. The clinic does not name its compounding pharmacy, and compounded sterile products are not FDA-reviewed for purity and potency the way approved drugs are. The named peptides sit on very different footing, and the site does not say so. BPC-157 and TB-500, the two halves of the Wolverine blend, were on FDA's Category 2 compounding list until April 2026 and are not yet cleared for pharmacy compounding; a July 2026 advisory vote to add some to the 503A bulks list is non-binding. CJC-1295 and injectable GHK-Cu are in the same position. So ask what can actually be dispensed to you. On evidence, sermorelin, CJC-1295/ipamorelin and tesamorelin act on the growth-hormone axis, a real mechanism with thin long-term outcome data for wellness use; tesamorelin's approved evidence is for HIV-associated abdominal fat, and the compounded version is not that product. GHK-Cu, injectable glutathione, BPC-157 and TB-500 have essentially no controlled human outcome trials. Injected NAD⁺ has none either; oral NR and NMN raise blood NAD⁺, a biomarker rather than a benefit. The compounded retatrutide sold here is not an FDA-approved product. Individual results vary.